Olezarsen 80 mg significantly lowers both fasting and postprandial TG level in patients with hypertriglyceridaemia (HTG), with potential anti-atherogenic effects via reduction of residual inflammatory risk. These are the findings from research into postprandial responses to olezarsen reported by researchers from the Netherlands.1,2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
